<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635606</url>
  </required_header>
  <id_info>
    <org_study_id>HSDX-1801</org_study_id>
    <nct_id>NCT03635606</nct_id>
  </id_info>
  <brief_title>GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients</brief_title>
  <official_title>Validation of AKI-Sapere Model to Predict Patients at Risk for AKI After Cardiac Surgery: GUARD-AKI (GUiding Against Reserve Decline)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sapere Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WakeMed Health and Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sapere Bio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second&#xD;
      most common cause of hospital acquired AKI. The development of CSA-AKI is independently&#xD;
      associated with an increased risk of in-hospital death. There are currently no biomarkers&#xD;
      that could identify patients at higher risk for AKI and current risk predictor scores that&#xD;
      are based on clinical and demographic information are inadequate. Therefore, a diagnostic&#xD;
      test for predicting AKI risk in this clinical context would assist clinicians to optimize&#xD;
      surgical strategy and postoperative care to prevent CSA-AKI occurrence and improve patient&#xD;
      outcomes.&#xD;
&#xD;
      The primary purpose of this study is to validate a panel of biomarkers identified in the&#xD;
      discovery study (referred to as AKI-Sapere prognostic) to identify patients at risk for all&#xD;
      stages of CSA-AKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of stage 1 or higher postoperative AKI as defined by the KDIGO classification (stage 1 = sCr value of ≥0.3 mg/dL in the first 48h or a relative increase of ≥50% in peak sCr from baseline within 7 days post-surgery)</measure>
    <time_frame>within 7 days post-surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of moderate to severe AKI (sCr increase of ≥100% within 7 days post surgery or a sCr increase of ≥100% from baseline within 7 days and urine output &lt;0.5 mL/kg/h for &gt;12h)</measure>
    <time_frame>within 7 days post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of 30-day persistent kidney impairment (sCr increase of ≥0.5 mg/dL from baseline at the 30-day follow-up visit)</measure>
    <time_frame>30 days post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of worsening renal function (a 25% reduction in eGFR at the 30-day follow-up visit)</measure>
    <time_frame>30 days post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of 30-day major adverse kidney events (MAKE30): a composite of persistently impaired renal function (sCr increase of ≥0.5 mg/dL from baseline [pre-surgery]), new dialysis, and death</measure>
    <time_frame>30 days post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of 30-day major adverse cardiac events (MACE30): a composite of myocardial infarction (MI), stroke, heart failure, and death</measure>
    <time_frame>30 days post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of the combination of MAKE30 and MACE30 (major adverse reno-cardiovascular events [MARCE30])</measure>
    <time_frame>30 days post-surgery</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">592</enrollment>
  <condition>Coronary Artery Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects entered into this study will be patients at the participating institutions.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt;40 years) undergoing non-emergency (urgent or scheduled) cardiac&#xD;
             surgery using cardiopulmonary bypass (CABG or combined CABG/valve).&#xD;
&#xD;
          -  Patients must be able to understand English and be willing to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Off-pump coronary bypass grafting&#xD;
&#xD;
          -  Aortic aneurysm repair&#xD;
&#xD;
          -  Congenital heart disease repair&#xD;
&#xD;
          -  Heart transplant or left ventricular assist device patient&#xD;
&#xD;
          -  Severe heart failure (left ventricular ejection fraction &lt;25%)&#xD;
&#xD;
          -  Hemodynamic instability or requiring preoperative vasopressors or IABP&#xD;
&#xD;
          -  Pre-existing kidney disease (eGFR &lt;30 mL/min/1.73 m2) or renal transplantation.&#xD;
&#xD;
          -  Presence of major active infection (chronic or acute, eg, sepsis, HIV, pneumonia)&#xD;
&#xD;
          -  Chronic liver disease/cirrhosis&#xD;
&#xD;
          -  Participation in an additional trial at the time of surgery or anytime within 30d of&#xD;
             surgery where intervention could potentially alter renal health (unless in the control&#xD;
             arm)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia Mitin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapere Bio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lena Randhawa, PhD</last_name>
    <phone>919-886-4553</phone>
    <email>lena.randhawa@sapere-bio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia Mitin, PhD</last_name>
    <email>natalia.mitin@sapere-bio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Taylor</last_name>
      <email>Terry.Taylor@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Asad Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Parish</last_name>
      <email>maparish@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Aliaksei Pustavoitau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WakeMed Health and Hospitals</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Norton</last_name>
      <email>rnorton@wakemed.org</email>
    </contact>
    <investigator>
      <last_name>Judson Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

